Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 01/19 11:19:58 am
449.05 DKK   +2.23%
01/18NOVO NORDISK : Buy rating from JP Morgan
MD
01/15NOVO NORDISK A/S : Deutsche Bank Initiates Coverage on Novo Nordisk A/S With Buy Rating
MT
01/15European ADRs Move Sharply Lower in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk A/S : set to acquire Emisphere for $1.8 billion

11/12/2020 | 08:02am EST
Novo Nordisk to acquire Emisphere

Novo Nordisk has announced that is set to acquire Emisphere Technologies for $1.8 billion. Emisphere is a drug delivery company with proprietary technologies, such as the Eligen® SNAC technology, which enables the oral formulation of therapeutics.

According to Novo Nordisk, the companies have collaborated since 2007 and Emisphere's Eligen SNAC is used under an existing licence agreement in the oral formulation of Novo Nordisk's GLP-1 receptor agonist Rybelsus (semaglutide).

Under the terms of the agreement, Novo Nordisk will acquire all outstanding shares of Emisphere for $1.350 billion. As part of the transaction, Novo Nordisk will also acquire related Eligen SNAC royalty stream obligations owed to MHR Fund Management LLC (MHR), the largest shareholder of Emisphere, for $450 million. This brings the total acquisition price to the $1.8 billion.

According to the companies, the acquisition is expected to have a net negative impact on operating profit of less than one percent in 2021 and broadly neutral to positive impact in the following years.

“The acquisition of Emisphere provides Novo Nordisk full ownership of the Eligen SNAC technology, which has been successfully used under a licence agreement to develop the first oral biologic, Rybelsus," said Mads Krogsgaard Thomsen, Executive Vice President and Chief Scientific Officer of Novo Nordisk. "We intend to apply and further develop the technology and use it on current and future pipeline assets with the aim of making more biologic medicines orally available for patients."

The transaction is subject to customary closing conditions, including approval by Emisphere shareholders and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. MHR and certain other shareholders of Emisphere, collectively owning a majority of the Emisphere shares, have agreed to vote their shares in favour of the transaction.

Merck to acquire VelosBio for $2.75 billion…

The post Novo Nordisk set to acquire Emisphere for $1.8 billion appeared first on European Pharmaceutical Review.

© Russell Publishing Limited, 2020. All Rights Reserved., source Trade Journals

Stocks mentioned in the article
ChangeLast1st jan.
EMISPHERE TECHNOLOGIES, INC. 0.13% 7.81 End-of-day quote.0.00%
NOVO NORDISK A/S 2.17% 448.8 Delayed Quote.2.95%
All news about NOVO NORDISK A/S
01/18NOVO NORDISK : Buy rating from JP Morgan
MD
01/15NOVO NORDISK A/S : Deutsche Bank Initiates Coverage on Novo Nordisk A/S With Buy..
MT
01/15European ADRs Move Sharply Lower in Friday Trading
MT
01/15PRESS RELEASE : BP p.l.c.: BP announces non-executive director resignation
DJ
01/15NOVO NORDISK : Buy rating by Deutsche Bank
MD
01/11NOVO NORDISK A/S : – Share repurchase programme
AQ
01/11ZUR ROSE : Joins Novo Nordisk to Offer Health Services for Obese People
MT
01/07WERNER LANTHALER : Evotec to attend upcoming investor conferences
DJ
01/06European ADRs Climb Sharply Higher in Wednesday Trading
MT
01/06DICERNA PHARMACEUTICALS : Announces Novo Nordisk's Nomination of First Candidate..
AQ
More news
Financials
Sales 2020 127 B 20 722 M 20 722 M
Net income 2020 42 089 M 6 871 M 6 871 M
Net cash 2020 7 191 M 1 174 M 1 174 M
P/E ratio 2020 24,9x
Yield 2020 2,00%
Capitalization 1 037 B 169 B 169 B
EV / Sales 2020 8,12x
EV / Sales 2021 7,66x
Nbr of Employees 44 326
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 452,78 DKK
Last Close Price 448,80 DKK
Spread / Highest target 22,5%
Spread / Average Target 0,89%
Spread / Lowest Target -32,0%
EPS Revisions
Managers and Directors
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S2.95%164 819
JOHNSON & JOHNSON3.43%421 997
ROCHE HOLDING AG1.93%303 276
NOVARTIS AG1.65%217 178
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.22%203 993